ANI Pharmaceuticals (ANIP) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of ANI Pharmaceuticals (NASDAQ: ANIP) recently:

• 9/18/2024 – ANI Pharmaceuticals had its price target raised by analysts at Raymond James from $81.00 to $83.00. They now have an “outperform” rating on the stock.
• 9/17/2024 – ANI Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
• 9/11/2024 – ANI Pharmaceuticals had its “hold” rating reaffirmed by analysts at Truist Financial Co.. They now have a $60.00 price target on the stock, down previously from $80.00.
• 9/7/2024 – ANI Pharmaceuticals was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 8/27/2024 – ANI Pharmaceuticals was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 8/7/2024 – ANI Pharmaceuticals was downgraded by analysts at Truist Financial Co. from a “strong-buy” rating to a “hold” rating.
• 8/7/2024 – ANI Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.

ANI Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:ANIP opened at $61.05 on Thursday. The company has a market capitalization of $1.28 billion, a PE ratio of 38.16 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The business has a fifty day moving average price of $61.22 and a two-hundred day moving average price of $63.78. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm’s quarterly revenue was up 18.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.06 EPS. Analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Muthusamy Shanmugam sold 11,000 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $63.38, for a total transaction of $697,180.00. Following the sale, the chief operating officer now owns 671,620 shares of the company’s stock, valued at approximately $42,567,275.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 11,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $63.38, for a total value of $697,180.00. Following the sale, the chief operating officer now owns 671,620 shares of the company’s stock, valued at approximately $42,567,275.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the sale, the senior vice president now directly owns 193,226 shares in the company, valued at approximately $12,258,257.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,007 shares of company stock valued at $4,089,790. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after acquiring an additional 17,460 shares during the last quarter. Rubric Capital Management LP grew its position in ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after acquiring an additional 277,989 shares during the last quarter. Dimensional Fund Advisors LP grew its position in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after acquiring an additional 21,053 shares during the last quarter. Ranger Investment Management L.P. grew its position in ANI Pharmaceuticals by 1.8% during the 4th quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after acquiring an additional 7,769 shares during the last quarter. Finally, Millennium Management LLC grew its position in ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock worth $14,651,000 after acquiring an additional 209,272 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.